VK-2019

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameVK-2019
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpstein-Barr nuclear antigen 1 inhibitors
TargetsEpstein-Barr nuclear antigen 1
Therapy Area/IndicationsNasopharyngeal NeoplasmsNasopharyngeal CarcinomaLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeFrance +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCullinan Therapeutics IncWistar Institute
China Registration ClassN/A

Develop Information

Active CompaniesStanford UniversityThomas Jefferson UniversityEmerson Resources Inc +[5] 
Inactive CompaniesCullinan Therapeutics Inc
Active IndicationsNasopharyngeal NeoplasmsLymphoma, Large B-Cell, DiffuseEpstein-Barr Virus Infections
Inactive IndicationsNasopharyngeal Carcinoma

Other Information

ATC CodeN/A
Related LinksN/A